New drug combo targets tough cancers in early trial
NCT ID NCT07563738
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ODM-212 combined with other cancer treatments in people with advanced solid tumors, including mesothelioma, pancreatic cancer, and non-small cell lung cancer. The trial has two parts: first finding a safe dose, then checking how well it works. About 229 adults with tumors that cannot be removed by surgery will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NEXT Oncology
RECRUITINGIrving, Texas, 75039, United States
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?
- Can a pill rouse the immune system against pancreatic cancer?